Attend the first and only summit focusing on the evolving economic and commercial landscape for rare diseases and orphan drugs.
In the past five years, 39 orphan drugs were launched in the US across numerous therapeutic categories, including multiple myeloma, chronic myelogenous leukemia, metastatic non-small cell lung cancer, hemophilia, tuberculosis, homozygous familial hypercholesterolemia, and cystic fibrosis. In 2013 alone, nine orphan drugs were approved, the most in a single year. The growing number of commercially available orphan drugs and the high cost of various orphan treatments have led to reconsideration of payer reimbursement policies.
Assess methods to increase orphan drug speed to market at a lower price to the patient.
Discuss the impending economic evolution in the rare disease landscape with senior executives.
Understand factors affecting reimbursement and formulary decisions Benchmark strategies for pricing and cost saving valuation of orphan drugs.
Discover recent findings on global orphan drug patient access issues from a Tufts Center for the Study of Drug Development Impact Report.
Send this to friend